Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-05

Clinical Trial Update: Januvia Re-examination Study (MK-0431-181)

View source ↗

Summary

The Januvia re-examination study MK-0431-181 for type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Januvia (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Status: COMPLETED